Literature DB >> 9784556

Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.

L J Rubinstein1, P A García-Ojeda, F Michon, H J Jennings, K E Stein.   

Abstract

The polysaccharide (PS) capsules of many pathogenic bacteria are poor immunogens in infants and young children as a result of the delayed response to PS antigens during ontogeny. The development of polysaccharide-protein conjugate vaccines for Haemophilus influenzae type b, which have proven to be efficacious in this age group, has led to active development by a number of investigators of conjugate vaccines for other diseases. We describe here the response of several mouse strains to the capsular PS of Neisseria meningitidis group C (MCPS) conjugated to tetanus toxoid (MCPS-TT) and the same response in BALB/c mice as a model of the immune consequences of conjugate vaccine immunization. The use of a conjugate vaccine results in a shift in the isotype elicited in response to the MCPS, from immunoglobulin M (IgM) and IgG3 to primarily IgG1. A response to MCPS-TT is seen even among mouse strains which respond poorly to MCPS itself, emphasizing the importance of a strain survey when choosing a mouse model for a vaccine. The marked increase in IgG1 antibody titer was accompanied by a large increase in bactericidal activity of sera from these animals. Animals primed with the conjugate vaccine demonstrated a booster response after secondary immunization with either the MCPS or the conjugate. The ability to produce a boosted IgG1 anti-MCPS response to the MCPS can be transferred to adoptive recipients by B cells alone from mice primed with MCPS-TT but not mice primed with MCPS alone. These data indicate that in BALB/c mice a single immunization with MCPS-TT is sufficient to induce a shift to IgG1 and generate a memory B-cell population that does not require T cells for boosting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784556      PMCID: PMC108682     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  63 in total

1.  Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster.

Authors:  R Booy; P T Heath; M P Slack; N Begg; E R Moxon
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

2.  Phase I study of the immunogenicity and safety of conjugated Hemophilus influenzae type b vaccines in the elderly.

Authors:  E Kantor; J S Luxenberg; A H Lucas; D M Granoff
Journal:  Vaccine       Date:  1997-02       Impact factor: 3.641

3.  Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines.

Authors:  E C Beuvery; F Miedema; R van Delft; J Haverkamp
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

4.  Safety and immunogenicity of a Haemophilus influenzae type b conjugate vaccine in a high risk American Indian population.

Authors:  M Santosham; J Hill; M Wolff; R Reid; L Lukacs; V Ahonkhai
Journal:  Pediatr Infect Dis J       Date:  1991-02       Impact factor: 2.129

5.  Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.

Authors:  M A Shelly; H Jacoby; G J Riley; B T Graves; M Pichichero; J J Treanor
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

6.  A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants.

Authors:  P A Twumasi; S Kumah; A Leach; T J O'Dempsey; S J Ceesay; J Todd; C V Broome; G M Carlone; L B Pais; P K Holder
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

7.  Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization.

Authors:  S J Ceesay; S J Allen; A Menon; J E Todd; K Cham; G M Carlone; S H Turner; L L Gheesling; W DeWitt; B D Plikaytis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

8.  The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex.

Authors:  M Santosham; M Wolff; R Reid; M Hohenboken; M Bateman; J Goepp; M Cortese; D Sack; J Hill; W Newcomer
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

9.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

10.  Susceptibility of different strains of mice to hepatic infection with Plasmodium berghei.

Authors:  L F Scheller; R A Wirtz; A F Azad
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

View more
  8 in total

1.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

2.  A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice.

Authors:  Ulrike K Buchwald; Andrew Lees; Michael Steinitz; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  Murine immune response to Neisseria meningitidis group C capsular polysaccharide: analysis of monoclonal antibodies generated in response to a thymus-independent antigen and a thymus-dependent toxoid conjugate vaccine.

Authors:  P A García-Ojeda; M E Monser; L J Rubinstein; H J Jennings; K E Stein
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

4.  Surface plasmon resonance analysis of antipolysaccharide antibody specificity: responses to meningococcal group C conjugate vaccines and bacteria.

Authors:  Pablo A García-Ojeda; Sharon Hardy; Steven Kozlowski; Kathryn E Stein; Ian M Feavers
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

5.  Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses.

Authors:  David S Berry; Freyja Lynn; Che-Hung Lee; Carl E Frasch; Margaret C Bash
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

6.  Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine.

Authors:  Nikolas T Weissmueller; Leanne Marsay; Heiko A Schiffter; Robert C Carlisle; Christine S Rollier; Robert K Prud'homme; Andrew J Pollard
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

7.  Vaccine-Induced Carbohydrate-Specific Memory B Cells Reactivate During Rodent Malaria Infection.

Authors:  Hayley Joseph; Qiao Ye Tan; Ramin Mazhari; Emily M Eriksson; Louis Schofield
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

8.  Bioorthogonal, Bifunctional Linker for Engineering Synthetic Glycoproteins.

Authors:  Ryan McBerney; Jonathan P Dolan; Emma E Cawood; Michael E Webb; W Bruce Turnbull
Journal:  JACS Au       Date:  2022-08-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.